drugset / Trial / NCT02661815
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.
Timeline
- Start
- 2016-06-15
- Primary completion
- 2017-06-28
- Completion
- 2017-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Ricolinostat | Small molecule | — | Oral |